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It has been clear for some time that the tumor suppressor PTEN 
shuttles in and out of the nucleus. Furthermore, many lines 
of evidence imply that this nuclear localization has a big in-
fluence on the activities of PTEN, which control cell behavior 
and block tumor formation. However, detailed understanding of 
how PTEN gets in and out of the nucleus and how this affects 
PTEN function has been slow to develop.
The first well-controlled studies of PTEN expression and 
localization in tissue samples from cancer patients provided a 
consistent but puzzling picture. In several normal tissues, PTEN 
appeared to be largely nuclear, but in tumors PTEN was either 
absent or largely observed in the cytosol (Gimm et al., 2000; 
Perren et al., 2000; Tachibana et al., 2002). A picture steadily 
emerged that nuclear PTEN was a good thing. However, simul-
taneously strong evidence established that PTEN is a lipid phos-
phatase that acts on a substrate almost exclusively located within 
the plasma membrane, phosphatidylinositol 3,4,5-trisphosphate 
(PIP3; Worby and Dixon, 2014). It also became clear that PIP3 
metabolism is the dominant mechanism of tumor suppression 
by PTEN. To address this conundrum, several studies have pro-
posed that PTEN fulfils novel tumor suppressor functions in 
the nucleus unrelated to its PIP3 phosphatase activity (Worby 
and Dixon, 2014). However, the finding by two independent re-
search groups that mice expressing mutant PTEN proteins that 
selectively lack lipid phosphatase activity develop worse tumors 
than mice expressing no PTEN argues strongly against PTEN 
having dominant tumor suppressor functions that act fully inde-
pendently of its PIP3 phosphatase activity. This leaves the ques-
tion of why nuclear PTEN correlates with tumor suppression.
Like many proteins, the function of PTEN is controlled 
in part by ubiquitination—the covalent ligation of units of the 
small regulatory protein ubiquitin. The addition of a single 
ubiquitin unit to PTEN seems to promote a nuclear localization 
for PTEN. In contrast, as seen with many proteins, the addition 
of multiple linked ubiquitin units targets PTEN for destruc-
tion. Further pieces of this complex puzzle have been provided. 
Several lysine residues on PTEN have been identified that can 
carry ubiquitin (Trotman et al., 2007; Gupta and Leslie, 2016). 
Several ubiquitin E3 ligases have been shown to couple ubiqui-
tin onto PTEN (Wang et al., 2007; Van Themsche et al., 2009; 
Maddika et al., 2011; Ahmed et al., 2012; Lee et al., 2013, 2015; 
Li et al., 2014) and conversely enzymes that remove ubiquitin 
from PTEN have been identified. However, details of how these 
enzymes influence PTEN function, where in cells they act, and 
how these ubiquitin chain linkages are extended and at which of 
the sites on PTEN has been largely unknown.
In new research published in this issue, Chen et al. provide 
strong evidence that the importin β family member Importin-11 
(IPO11) binds to PTEN and transports it into the nucleus. In 
prostate cancer cells lacking IPO11 function, PTEN was found 
to be much more cytoplasmic at steady state than control cells 
and in dynamic experiments IPO11 disruption greatly slowed 
down entry of PTEN into the nucleus. Importantly, if IPO11 
was stopped from taking PTEN into the nucleus, not only did 
this stop accumulation of PTEN in the nucleus but also greatly 
reduced the level of PTEN protein expression without affecting 
the abundance of its mRNA. These data are consistent with the 
idea that PTEN may be degraded in the cytoplasm and fits with 
proposed roles of the HECT domain containing E3 ubiquitin 
ligase NEDD4 and its binding partner NDF IP1 in promoting 
PTEN degradation and with their expected cellular locations. 
However, hints that disruption of IPO11 function reduced 
PTEN levels far more strongly than simply excluding PTEN 
itself from the nucleus motivated the authors to investigate 
other recognized IPO11 cargo proteins that might contribute 
to the regulated destruction of PTEN. When tested, one such 
IPO11 cargo, the E2 ubiquitin–conjugating enzyme UBE2E1, 
was shown to drive PTEN ubiquitination in cells when over-
expressed and to be required for the degradation of PTEN 
caused by loss of IPO11.
This led Chen et al. (2017) to propose a “relay break” 
model in which PTEN is monoubiquitinated on Lys13 and/or 
Lys289 promoting binding to IPO11, which in turn traffics both 
this monoubiquitinated PTEN and UBE2E1 into the nucleus 
(Fig. 1). This separates PTEN from the cytoplasmic E3 ubiq-
uitin ligases such as NEDD4 and its Golgi membrane–located 
binding partner NDF IP1, which would drive PTEN polyubiq-
uitination and degradation. It also separates the E2 component 
UBE2E1 from the E3 NEDD4–NDF IP complex. It is recog-
nized that such a model is affected by PTEN nuclear export and 
deubiquitination, which are less clearly understood.
To investigate whether IPO11 affected the functions of 
PTEN as a tumor suppressor, Ipo11 mutant hypomorphic mice 
that carry an exogenous splice acceptor site in the Ipo11 gene 
In this issue, Chen et al. (2017. J. Cell Biol. https ://doi 
.org /10 .1083 /jcb .201604025) show that Importin-11 
traffics the tumor suppressor PTEN into the nucleus and in 
so doing protects it from cytoplasmic proteins that cause 
PTEN degradation. This work helps explain the nuclear 
accumulation of PTEN observed in many healthy tissues 
and, because Ipo11 mutant mice develop lung tumors, 
also implicates Importin-11 as a novel tumor suppressor.
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to reduce its expression level were bred. Homozygous Ipo11 
hypomorphs are born at lower frequencies than expected, indi-
cating some embryonic lethality. In addition, whereas in some 
tissues and organs (e.g., mouse embryo fibroblasts and lung 
tissue) IPO11 expression was greatly reduced, in others, such 
as excised prostates, IPO11 expression appeared normal. Lung 
tumors were observed in the Ipo11 mutant mice and their tu-
mor-free survival was significantly worse than a control cohort. 
These lung tumors, mostly adenomas and adenocarcinomas, 
showed low staining for IPO11 and PTEN and weak diffuse 
UBE2E3 expression, indicating little IPO11 function. The tu-
mors also showed high levels of P-AKT and Ki67 staining, 
indicating enhanced growth signaling and cell proliferation, 
respectively. Although it is clearly possible that these lung tu-
mors are driven by other factors such as disturbances in the 
function of other IPO11 cargo proteins, the data do suggest that 
IPO11 acts as a tumor suppressor at least in part by traffick-
ing and protecting PTEN.
Following on from these mouse studies, Chen et al. (2017) 
looked at human clinical data for evidence of loss of IPO11 
function in human cancers as would be predicted if it acts as a 
tumor suppressor. This revealed a highly significant correlation 
between reduced levels of IPO11 and reduced levels of PTEN 
seen in approximately half of the large cohort of lung cancer 
tissue samples. However, no evidence for loss of expression at 
the mRNA level was seen, consistent with the idea that IPO11 
acts directly on the PTEN protein. Correlations were also ob-
served in prostate cancer between IPO11 loss and poor clinical 
outcomes and progressive metastatic disease.
Of course new questions are raised by this work and old 
ones remain regarding many aspects of PTEN ubiquitination 
and regulation. For example, does PTEN need other factors 
and inputs to stop its cytosolic destruction if it is to accumulate 
there and access PIP3 in the plasma membrane? Also, it is still 
unclear where and how the many different proposed E3 ubiqui-
tin ligases and ubiquitin proteases act on PTEN and even less 
clear whether blocking PTEN degradation represents a viable 
target for therapeutic intervention. However, the study by Chen 
et al. (2017) provides some important new pieces in the com-
plex PTEN regulatory jigsaw puzzle. It also identifies IPO11 as 
a possible new tumor suppressor. Loss of one IPO11 gene copy 
has been observed at high frequencies (>30%) in many cancer 
genomic datasets, including lung cancer studies, and although 
other neighboring genes may contribute to driving these dele-
tions (including, e.g., the PIK3R1 gene), the in vivo tumori-
genesis data of Chen et al. (2017) argues strongly that IPO11 
is likely to be individually important as a tumor suppressor in 
many of these cases. The observation that only some tissues 
(e.g., lung) in the authors’ IPO11 mutant mouse had substantial 
reductions in IPO11 expression leaves open the possibility that 
the IPO11–PTEN axis may be important in many more cancer 
types and seems likely to be the subject of further study.
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Figure 1. PTEN nuclear import and ubiquitination. 
Chen et al. (2017) propose a “relay break” model for 
the regulation of PTEN degradation (see Fig. 4 E in 
Chen et al., 2017). PTEN, which is monoubiquitinated 
(Ub) in the cytosol and primed for further polyubiquiti-
nation, marking it for degradation, is also a substrate 
for import into the nucleus by IPO11. One effect of 
nuclear import is to protect PTEN from cytosolic deg-
radation initiated by E3 ubiquitin ligase components, 
including NEDD4. IPO11 also traffics the activated 
UBE2E1 E2 ubiquitin–conjugating enzyme into the nu-
cleus, separating it from cytosolic enzymes that could 
combine with UBE2E1 to promote the polyubiquiti-
nation of PTEN. PTEN deubiquitination and nuclear 
export are recognized but how these actions comple-
ment IPO11-driven nuclear import is unclear.
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